ASH 2023 | Outcomes of patients with MCL who require urgent treatment at time of diagnosis
Jonathon Cohen, MD, MS, Emory University School of Medicine, Atlanta, GA, briefly comments on patients with mantle cell lymphoma (MCL) who have high-risk disease and require urgent treatment at diagnosis. Dr Cohen highlights that these patients have a poor prognosis and should be the focus when developing new therapies and clinical trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research Funding: BMS/Celgene, Novartis, Genentech, BioInvent, Lam Therapeutics, Takeda, AstraZeneca, Loxo/Lilly
Consultancy: ADCT, AstraZeneca, Abbvie, Janssen, BeiGene, Loxo/Lilly
